Jackson Wealth Management LLC Has $6.54 Million Position in Cencora, Inc. (NYSE:COR)

Jackson Wealth Management LLC cut its position in Cencora, Inc. (NYSE:COR) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 29,087 shares of the company’s stock after selling 194 shares during the quarter. Jackson Wealth Management LLC’s holdings in Cencora were worth $6,535,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. acquired a new position in Cencora in the fourth quarter valued at about $205,000. E. Ohman J or Asset Management AB lifted its position in shares of Cencora by 4.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 7,800 shares of the company’s stock worth $1,753,000 after purchasing an additional 300 shares in the last quarter. Mather Group LLC. lifted its position in shares of Cencora by 2.3% during the fourth quarter. Mather Group LLC. now owns 2,615 shares of the company’s stock worth $588,000 after purchasing an additional 58 shares in the last quarter. Childress Capital Advisors LLC lifted its position in shares of Cencora by 3.5% during the fourth quarter. Childress Capital Advisors LLC now owns 1,572 shares of the company’s stock worth $353,000 after purchasing an additional 53 shares in the last quarter. Finally, Oregon Pacific Wealth Management LLC acquired a new position in shares of Cencora during the fourth quarter worth approximately $281,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of a number of research reports. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Barclays upped their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Evercore ISI upped their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird boosted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $278.40.

Cencora Stock Down 1.2 %

Shares of COR stock opened at $251.31 on Wednesday. The firm has a fifty day moving average of $239.00 and a 200-day moving average of $236.39. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $261.25. The company has a market capitalization of $48.57 billion, a price-to-earnings ratio of 33.46, a P/E/G ratio of 1.59 and a beta of 0.49.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.